

GenomeCure Therapeutics GmbH - Q3 2024 Investor Update

Direct Investment: GenomeCure Therapeutics GmbH

Investment Type: PRIVATE_EQUITY

Document Type: INVESTOR_UPDATE

Upload Date: 30 Jul 2024

Period: Q3 2024

Period Date: 30 Jul 2024

Highlights:

- Completed Phase 1 clinical trials successfully
- EMA granted PRIME designation
- Published positive data in Nature Medicine
- Partnered with Roche for distribution

Lowlights:

- Phase 2 trials delayed by 6 months
- Patient recruitment slower than expected
- Manufacturing scale-up challenges

Milestones:

- Initiated Phase 2 trials in oncology
- Received €3M Horizon Europe grant
- Hired former Novartis CMO
- Filed 3 new patent applications

Metrics Snapshot:

Revenue: €420,000

Burn: €65,000

Runway (months): 18

Headcount: 42

Cash Balance: €320,000